List of Excipients in Branded Drug MYDAYIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	MYDAYIS	dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	54092-468	FD&C BLUE NO. 2
Takeda Pharmaceuticals America Inc	MYDAYIS	dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	54092-468	FERRIC OXIDE YELLOW
Takeda Pharmaceuticals America Inc	MYDAYIS	dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	54092-468	GELATIN

Mydayis Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Mydayis is an extended-release mixed amphetamine salts product with a differentiated multiparticulate delivery system. Its commercial value is tied less to novel active pharmaceutical ingredient chemistry than to release control, capsule manufacture, excipient functionality, regulatory reproducibility, and abuse-deterrence positioning. The strongest opportunities are in functional excipients, multiparticulate coating technologies, generic development, contract manufacturing, and lifecycle extensions.

Mydayis is marketed by Takeda Pharmaceuticals USA for attention-deficit/hyperactivity disorder, or ADHD. The product is available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg capsules. FDA approval was granted in 2017 under NDA 022063.[1]

What excipients are used in Mydayis capsules?

Mydayis uses a multiparticulate capsule system containing drug-loaded beads with different release profiles. The formulation includes polymeric coating materials, pelletization excipients, capsule-shell components, and colorants.

Public labeling identifies the following inactive ingredients or excipient classes:

Excipient or excipient class	Likely formulation role
Sugar spheres	Inert cores for drug layering and pellet formation
Hypromellose	Binder, film former, and drug-layering aid
Ethylcellulose	Water-insoluble release-controlling polymer
Dibutyl sebacate	Plasticizer for polymer coatings
Povidone	Binder and processing aid
Talc	Anti-tacking and coating-process aid
Gelatin	Hard-capsule shell
Titanium dioxide	Opacifier and colorant
FD&C colorants	Strength and product identification
Purified water and processing solvents	Granulation and coating media, removed during manufacture

The precise function of each material depends on the bead layer. Mydayis is not adequately characterized as a conventional hydrophilic matrix tablet. Its performance depends on coated multiparticulates with staggered drug release.

How does Mydayis use multiparticulate release technology?

Mydayis contains three types of drug-releasing beads designed to provide immediate, delayed, and extended release. The capsule is intended to produce therapeutic exposure for up to approximately 16 hours in adults, subject to individual pharmacokinetic variability.[1]

The formulation strategy has four commercial implications:

1. Drug release is distributed across multiple bead populations rather than controlled by a single tablet matrix.
2. Polymer coating thickness and uniformity are critical quality attributes.
3. Excipient substitution can change dissolution, food effects, and dose proportionality.
4. Generic developers must reproduce the product’s in vitro and in vivo performance, not merely match the active ingredient.

The key excipient value is functional performance. A low-cost substitution that changes coating permeability, plasticizer migration, pellet porosity, or capsule disintegration can create bioequivalence and manufacturing problems.

What excipients are most commercially important for Mydayis?

Ethylcellulose and other release-controlling polymers

Ethylcellulose is the principal commercial opportunity among Mydayis-related excipient classes. It provides a water-insoluble coating that controls drug diffusion and protects pellet integrity during processing and storage.

Potential suppliers compete on:

• Viscosity grade
• Particle-size distribution
• Substitution level
• Organic-solvent or aqueous-dispersion processability
• Batch-to-batch permeability
• Regulatory documentation
• Residual-solvent profile
• Global compendial status

Polymer grade is commercially important because nominal chemical equivalence does not guarantee equivalent dissolution performance. Differences in viscosity, coating morphology, or dispersion behavior can alter the release curve.

Hypromellose

Hypromellose can function as a drug-layering binder and film-forming material. It supports uniform deposition of amphetamine salts onto sugar spheres and can influence wetting, mechanical strength, and downstream coating adhesion.

The strongest supplier proposition is not generic hypromellose availability. It is validated performance in fluid-bed drug layering and compatibility with the specific bead manufacturing process.

Dibutyl sebacate

Dibutyl sebacate acts as a plasticizer for polymer films. It improves flexibility and reduces cracking during coating, handling, and storage.

Plasticizer selection can affect:

• Film elasticity
• Water permeability
• Coating coalescence
• Thermal behavior
• Long-term dissolution stability
• Extractables and leachables

Alternative plasticizers may create lifecycle opportunities, but they also raise comparability risk. A substitution that produces a stronger or weaker film may shift release timing.

Sugar spheres

Sugar spheres are the substrate for drug layering. Their size distribution, friability, surface roughness, and moisture content affect drug loading and coating uniformity.

Commercial opportunities include:

• Narrower particle-size distributions
• Lower-friability starter pellets
• Improved surface morphology
• Higher drug-loading efficiency
• More consistent fluid-bed processing
• Non-sugar starter cores for modified-release products

Starter-core suppliers may gain value through process qualification rather than ingredient exclusivity. Once a bead process is validated, manufacturers are reluctant to change core specifications without a clear cost or performance benefit.

What formulation patents protect Mydayis?

Mydayis protection is likely to include formulation and release-profile claims directed to multiparticulate amphetamine compositions, bead populations, delayed-release structures, extended-release delivery, and methods of treating ADHD.

The practical patent analysis has three layers:

Protection layer	Commercial relevance
Active ingredient claims	Limited, because mixed amphetamine salts are established active ingredients
Multiparticulate formulation claims	Potentially important for generic design-around analysis
Method-of-use claims	May affect labeling, indication, and certain launch strategies

The FDA Orange Book should be reviewed for current listed patents, expiration dates, pediatric extensions, and any regulatory exclusivity associated with NDA 022063.[2] Patent expiry and enforceability must be evaluated separately. A listed patent can remain a Paragraph IV litigation trigger even when its commercial blocking strength is narrower than the product label suggests.

How strong is the Mydayis patent estate?

The estate is strongest where claims capture the combination of:

• Multiple bead populations
• Distinct release windows
• Amphetamine salt loading
• Polymer-coated pellets
• Extended duration
• ADHD treatment methods linked to the dosage form

The estate is weaker where a claim depends on broadly available excipients without a narrow structural or performance limitation. Ethylcellulose, hypromellose, sugar spheres, and standard plasticizers are established pharmaceutical materials. Their presence alone is unlikely to create durable exclusivity.

The principal barrier is therefore the integrated manufacturing process and release profile, not ownership of the individual excipients.

When does Mydayis lose exclusivity?

Mydayis received FDA approval in 2017. FDA regulatory exclusivity and patent exclusivity are separate. New chemical entity exclusivity, if applicable to the approved product, generally lasts five years from approval, subject to the statutory framework and any Paragraph IV filing rules.[3]

The commercial entry date depends on:

• Current Orange Book-listed patents
• Any pediatric exclusivity
• Paragraph IV certifications
• Litigation stays
• Settlement agreements
• Generic product approval timing
• Whether an applicant can obtain approval with a different label
• Manufacturing readiness and controlled-substance compliance

No single approval date establishes the first lawful generic launch. The relevant date is the earliest enforceable launch date after regulatory and patent barriers are resolved.

What generic entry risks exist for Mydayis?

Generic developers face several risks:

1. Matching the multiparticulate release profile.
2. Demonstrating bioequivalence across all strengths.
3. Controlling bead-size distribution and coating thickness.
4. Reproducing dissolution under multiple media and agitation conditions.
5. Addressing food-effect requirements.
6. Managing amphetamine-salt content uniformity.
7. Operating under controlled-substance manufacturing and distribution rules.
8. Avoiding patented formulation or method claims.

A generic applicant may pursue a Paragraph IV certification against listed patents. If the sponsor files a timely patent-infringement action, the FDA approval may be subject to a statutory stay of up to 30 months, subject to litigation developments.[4]

What is the FDA regulatory status of Mydayis?

Mydayis is an FDA-approved prescription central nervous system stimulant for ADHD. Amphetamine products are controlled substances, creating additional manufacturing, inventory, distribution, and diversion-control requirements.[1,5]

The product’s regulatory value comes from its approved long-duration dosing profile. The label permits once-daily administration and supports a commercial position between shorter-duration mixed amphetamine salts products and other long-acting ADHD therapies.

FDA regulatory considerations for excipient changes include:

• Impact on dissolution
• Bioequivalence
• Stability
• Capsule performance
• Impurity profile
• Colorant and gelatin compliance
• Manufacturing-process validation
• Postapproval change reporting under FDA regulations

For a marketed product, an excipient substitution may require a prior-approval supplement, a changes-being-effected supplement, or annual-report documentation depending on the change and its effect on product quality.[6]

What commercial opportunities exist for Mydayis excipient suppliers?

1. Qualified-source supply

The most immediate opportunity is supply of qualified ethylcellulose, hypromellose, plasticizers, sugar spheres, and coating-process materials. Suppliers with FDA Drug Master Files, reliable global supply, and controlled particle or viscosity specifications have an advantage.

2. Generic formulation platforms

Generic developers can use Mydayis as a target product for multiparticulate controlled-release platforms. A successful platform may be transferable to:

• Long-acting ADHD medicines
• Opioid-free pain products
• Gastrointestinal delivery
• Pulsatile-release products
• Pediatric sprinkle formulations
• Once-daily CNS medicines

3. Excipient substitution

Cost reduction can come from alternate grades or suppliers, but the business case must include comparability studies, regulatory filing costs, process requalification, and possible clinical or bioequivalence work.

The best substitution candidates are materials with established compendial status and well-understood functionality. High-risk substitutions include the release-controlling polymer, plasticizer, starter-pellet core, and any excipient that materially affects coating permeability.

4. Pediatric and sprinkle-friendly delivery

Multiparticulate capsules can support pediatric administration strategies if the product is designed for opening and sprinkling without compromising release characteristics. This creates an opportunity for age-appropriate dosage forms, although any new administration method requires label, stability, safety, and bioequivalence support.

5. Contract development and manufacturing

CDMOs with fluid-bed coating, drug layering, bead encapsulation, and controlled-substance capabilities can compete for generic development and commercial supply. The equipment and quality systems required for amphetamine products narrow the field compared with noncontrolled oral solids.

How does Mydayis compare with Adderall XR?

Attribute	Mydayis	Adderall XR
Active ingredient	Mixed amphetamine salts	Mixed amphetamine salts
Dosage form	Extended-release capsule	Extended-release capsule
Release concept	Multiple bead populations with longer-duration profile	Biphasic bead-based release
Approved duration positioning	Up to approximately 16 hours in adults	Approximately 12 hours, depending on patient factors
Key formulation barrier	Multi-stage release and coating control	Dual-release bead architecture
Generic risk	High multiparticulate and profile-matching burden	Established generic competition and formulation complexity
Commercial differentiation	Longer intended duration and once-daily use	Broad historical use and established generic market

Both products rely on multiparticulate technology, but they should not be treated as interchangeable formulation targets. A generic platform developed for Adderall XR may provide technical knowledge but does not automatically establish bioequivalence to Mydayis.

What patent litigation and settlement issues affect Mydayis?

Patent litigation risk centers on Paragraph IV challenges to listed formulation or method patents. The relevant commercial questions are:

• Whether a generic applicant has filed a Paragraph IV certification
• Whether Takeda or an affiliate filed an infringement action
• Whether a 30-month stay applies
• Whether the parties entered a settlement
• Whether the settlement permits an authorized or licensed generic
• Whether the settlement contains supply, launch, or manufacturing restrictions

Public litigation databases and the Orange Book should be checked together. Orange Book listings identify regulatory patent barriers, while court records establish whether those patents were asserted and whether the case remains active.

What revenue exposure does Mydayis create?

Takeda does not generally report Mydayis as a separately disclosed revenue line in its principal public financial reporting. Product-level revenue, market share, and gross-margin exposure therefore cannot be reliably quantified from consolidated filings alone.[7]

The commercial exposure is concentrated in:

• ADHD prescription volume
• Price competition after generic entry
• Payer coverage and prior authorization
• Duration-based differentiation
• Controlled-substance supply continuity
• Prescriber adoption relative to Adderall XR, lisdexamfetamine, methylphenidate, and atomoxetine

Generic entry would likely pressure net price before it eliminates branded demand. The impact depends on the number of approved competitors, substitution rules, payer formularies, and whether Takeda supports an authorized generic.

What manufacturing and IP barriers protect Mydayis?

The most defensible barriers are operational:

• Controlled-substance handling
• Multiparticulate coating expertise
• Uniform drug layering
• Release-profile control
• Stability under long-term storage
• Capsule filling of mixed bead populations
• Regulatory experience with modified-release stimulants
• Commercial-scale reproducibility

These barriers can delay entry even when patent claims are vulnerable. They do not create permanent exclusivity. Once a generic manufacturer validates a robust bead process, the cost advantage can shift quickly toward scale, purchasing power, and payer access.

Key Takeaways

• Mydayis is a multiparticulate extended-release mixed amphetamine salts capsule approved by FDA in 2017.
• Its highest-value excipients are ethylcellulose, hypromellose, dibutyl sebacate, sugar spheres, and related coating-process materials.
• The commercial moat is the integrated bead architecture and release profile, not ownership of ordinary excipients.
• Generic developers face meaningful technical risk in coating uniformity, dissolution matching, food effects, and controlled-substance manufacturing.
• Excipient suppliers can compete through qualified grades, regulatory support, supply reliability, and validated fluid-bed performance.
• Generic entry timing depends on current Orange Book listings, Paragraph IV litigation, settlement terms, and FDA approval status.
• Mydayis and Adderall XR both use multiparticulate technology but have different release architectures and market positions.
• Product-level Mydayis revenue is not separately disclosed by Takeda in its principal public filings.

FAQs

Can ethylcellulose be replaced in a Mydayis generic?

Potentially, but replacement may alter coating permeability, dissolution, stability, and bioequivalence. A substitute polymer must be evaluated as a functional component, not only as a chemically similar excipient.

Is Mydayis protected by its active ingredient?

The mixed amphetamine salts active ingredient is established. Commercial protection is more likely to depend on the dosage form, release architecture, manufacturing process, and method-of-use claims.

Can a generic Mydayis capsule use different excipients?

Yes, a generic may use different inactive ingredients if it satisfies FDA requirements for quality, safety, bioequivalence, labeling, and pharmaceutical equivalence where applicable. Different excipients can increase development and regulatory risk.

Are Mydayis beads suitable for sprinkle administration?

The capsule’s multiparticulate design may support sprinkle-oriented development, but a new administration method requires specific product testing and regulatory support. The approved label controls permitted administration.

Which excipient suppliers are best positioned for Mydayis-related business?

Suppliers with established ethylcellulose, hypromellose, plasticizer, and starter-pellet products are best positioned when they can provide consistent specifications, regulatory files, global supply, and technical support for fluid-bed coating.

References

1. U.S. Food and Drug Administration. (2023). Mydayis prescribing information. Takeda Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Code. (2024). 21 U.S.C. § 355: New drugs.

4. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications and patent certifications.

5. U.S. Drug Enforcement Administration. (2024). Controlled substances act and drug scheduling resources. U.S. Department of Justice.

6. U.S. Food and Drug Administration. (2004). Changes to an approved NDA or ANDA: Guidance for industry. FDA.

7. Takeda Pharmaceutical Company Limited. (2024). Annual report and securities filings. Tokyo, Japan.